Kyleena

Levonorgestrel, the active ingredient in Kyleena, is a progestin presented as an intrauterine system for intrauterine use. The device releases levonorgestrel locally to provide continuous contraception, preventing pregnancy in women of reproductive age for up to five years.

GNH USA supplies Kyleena as a licensed, GDP‑compliant international pharmaceutical supplier, providing the intrauterine system to hospitals, pharmacies and clinics worldwide, and supporting global procurement with regulatory expertise and reliable logistics. Our network ensures timely delivery and compliance with local health authority requirements, and we also offer technical assistance for device insertion and patient counseling.

Kyleena, containing levonorgestrel, is used in the hormonal contraceptive pathway to prevent pregnancy.

Contraception: provides continuous prevention of pregnancy for up to five years. LARC (Long‑acting reversible contraception): offers a reversible, hormone‑based intrauterine method. Family planning: enables women to plan pregnancies with a single insertion and minimal maintenance.

Side effects are reported by some users of the intrauterine system.

Common Side Effects: - Irregular bleeding or spotting - Amenorrhea (absence of periods) - Pelvic or cramping pain - Breast tenderness - Headache - Acne or oily skin

Serious or Rare Side Effects: - Uterine perforation - Device expulsion - Pelvic inflammatory infection - Ectopic pregnancy - Ovarian cyst formation - Severe allergic reaction (anaphylaxis)

Before insertion, several precautions should be observed.

Screen for pregnancy: confirm the patient is not pregnant prior to device placement. Assess uterine anatomy: avoid use in women with known uterine anomalies or fibroids that distort the cavity. Check for active infection: postpone insertion if pelvic infection or sexually transmitted disease is present. Consider hormonal contraindications: do not use in patients with estrogen‑dependent tumours or severe liver disease. Monitor device position: schedule follow‑up examinations to detect displacement or expulsion. Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Levonorgestrel may interact with other medicines that affect hormone metabolism.

Major Interactions (Avoid): - Enzyme inducers (e.g., rifampin, carbamazepine, phenytoin): may markedly reduce levonorgestrel efficacy. - Antifungal azoles (e.g., ketoconazole, itraconazole): can increase levonorgestrel levels and risk of side effects. - HIV protease inhibitors (e.g., ritonavir): may alter hormone concentrations.

Moderate Interactions (Monitor Closely): - Certain antibiotics (e.g., rifampicin, griseofulvin): may modestly decrease contraceptive effectiveness. - Antiepileptic drugs with mixed enzyme activity: require clinical monitoring of contraceptive reliability.